Drug Trial Radar · NCT07027345
A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 11, 2025
Primary completion
Jan 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- BioMendics, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Northwestern University; Ann & Robert H Lurie Children's Hospital of Chicago; Stanford University; Lucile Packard Children's Hospital
- First posted
- Jun 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II clinical study will assess the efficacy, safety and tolerability of topical TolaSure Gel in adults and pediatric patients (2 years of age and older) diagnosed with localized, intermediate, or severe epidermolysis bullosa simplex (EBS). Each patient (40 to complete) will be enrolled in the study and will be randomized to receive either TolaSure Gel or a topical Placebo for daily application for 2-months. After 2-months, all patients will receive TolaSure Gel to daily apply for an additional 2-months. A remote follow-up visit will occur 2-months after the end of study. Total time in the study is 6-months. Localized patients will be applying study medication to their feet, with the option to treat their hands as well throughout the study. Intermediate and severe EBS patients will be applying study medication to randomized treatment area(s) (a minimum of \~2-3% Body Surface Area (BSA)), with the option to treat their feet as well throughout the study.
Conditions
- Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical GelDrug
TolaSure Topical Gel is applied once-daily to designated treatment areas for up to 4 months (Part 2 End of Study).
Topical Placebo GelDrug
Topical Placebo Gel is applied once-daily to designated treatment areas for up to 2 months (Part 1 End of Study).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Blister Surface Area of the Designated Treatment Area(s)Time frame: Day 1 (Baseline) and weekly until End of Study (2-months and maximum 4-months)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Stanford University School of Medicine, Dermatology Department
Palo Alto, California · Recruiting
NU Dermatolgy CTU
Chicago, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.